Quantum-Si (NASDAQ:QSI), Inc. (NASDAQ: QSI) is a life sciences technology company focused on the development of next-generation protein sequencing and characterization platforms. Founded in 2017 and headquartered in Guilford, Connecticut, the company has built a proprietary platform designed to enable researchers to sequence proteins at the single-molecule level. By combining microfluidics, advanced quantum sensor technologies and machine learning algorithms, Quantum-Si seeks to advance the field of proteomics with enhanced sensitivity and throughput compared to traditional mass spectrometry methods.
The core offering from Quantum-Si is the Infinity™ platform, which integrates sample preparation, fluidics control and a high-resolution quantum semiconductor detector. This system is intended to provide detailed protein identity and abundance data, empowering drug discovery, biomarker research and basic biological studies. Quantum-Si’s technology aims to tackle challenges such as low-abundance protein detection, post-translational modification mapping and complex sample analysis, supporting a broad range of applications in pharmaceutical R&D and clinical proteomics.
Quantum-Si collaborates with academic institutions, biotechnology firms and pharmaceutical companies worldwide, with customers and partners across North America, Europe and the Asia-Pacific region. The company has established strategic alliances for co-development projects, pilot studies and technology evaluations, positioning its platform as a complementary tool for existing proteomic workflows. Quantum-Si also offers reagent kits, consumables and technical support services to accelerate adoption and integration of its technology in research laboratories.
Leadership at Quantum-Si includes President and Chief Executive Officer Steve Rasmussen, who brings extensive experience in genomics and life science instrumentation, and Chief Financial Officer Mark Soudie. Under their guidance, the company has transitioned from early development into commercial readiness, expanding its engineering, operations and customer success teams. Quantum-Si continues to invest in R&D, manufacturing scale-up and global customer engagement to drive the next wave of proteomic innovation.
